• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Managing the drug treatment of rheumatoid arthritis.

作者信息

Wilsdon Tom D, Hill Catherine L

机构信息

School of Medicine, Nursing and Health Sciences, Flinders University, Adelaide.

School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide.

出版信息

Aust Prescr. 2017 Apr;40(2):51-58. doi: 10.18773/austprescr.2017.012. Epub 2017 Apr 3.

DOI:10.18773/austprescr.2017.012
PMID:28507397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5408004/
Abstract
摘要

相似文献

1
Managing the drug treatment of rheumatoid arthritis.类风湿关节炎的药物治疗管理
Aust Prescr. 2017 Apr;40(2):51-58. doi: 10.18773/austprescr.2017.012. Epub 2017 Apr 3.
2
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.美国类风湿关节炎患者使用生物制剂类改善病情抗风湿药物的经济负担。
Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1231-1241. doi: 10.1080/14737167.2022.2117690. Epub 2022 Sep 6.
3
Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.改善病情抗风湿药与细胞毒性药物在类风湿关节炎治疗中的作用。
Am J Med. 1988 Oct 14;85(4A):39-44. doi: 10.1016/0002-9343(88)90361-0.
4
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.在一组接受生物改善病情抗风湿药或托法替布治疗的类风湿关节炎患者中医疗资源的使用情况。
Clin Rheumatol. 2021 Apr;40(4):1273-1281. doi: 10.1007/s10067-020-05432-6. Epub 2020 Sep 30.
5
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.生物改善病情抗风湿药物（bDMARDs）、靶向合成 DMARDs（tsDMARDs）和生物类似物 DMARDs（bsDMARDs）联合甲氨蝶呤治疗泰国高疾病活动度类风湿关节炎患者的成本-效用分析。
BMC Health Serv Res. 2023 May 31;23(1):561. doi: 10.1186/s12913-023-09595-1.
6
Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis.预测类风湿关节炎患者初始甲氨蝶呤单药治疗后加用疾病修正抗风湿药物的因素。
Clin Rheumatol. 2021 Jul;40(7):2657-2663. doi: 10.1007/s10067-021-05599-6. Epub 2021 Jan 22.
7
Treatment Guidelines in Rheumatoid Arthritis.类风湿关节炎治疗指南
Rheum Dis Clin North Am. 2022 Aug;48(3):679-689. doi: 10.1016/j.rdc.2022.03.005. Epub 2022 Jul 5.
8
Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.调查德克萨斯州类风湿性关节炎医疗补助受助者开始使用生物性改善病情抗风湿药物的时间以及药物依从性和持续性。
Clin Ther. 2016 Mar;38(3):646-54. doi: 10.1016/j.clinthera.2016.01.022. Epub 2016 Feb 18.
9
Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?传统抗风湿病情改善药（DMARDs）在类风湿关节炎治疗中是否仍有作用？
Curr Opin Rheumatol. 2003 May;15(3):185-92. doi: 10.1097/00002281-200305000-00003.
10
Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis.疾病修饰抗风湿药物与帕金森病风险：类风湿关节炎患者的巢式病例对照研究。
Neurology. 2022 Mar 22;98(12):e1273-e1281. doi: 10.1212/WNL.0000000000013303. Epub 2022 Jan 21.

引用本文的文献

1
Displacement-encoded MRI reveals biomechanical stiffening in rheumatoid arthritis wrists: a case control study.位移编码磁共振成像揭示类风湿性关节炎手腕的生物力学僵硬：一项病例对照研究。
Sci Rep. 2025 Sep 2;15(1):32351. doi: 10.1038/s41598-025-17316-3.
2
Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy.微球药物平台在类风湿关节炎治疗中增强甲氨蝶呤给药的应用。
Pharmaceutics. 2024 Dec 13;16(12):1593. doi: 10.3390/pharmaceutics16121593.
3
Microneedles loaded with cerium-manganese oxide nanoparticles for targeting macrophages in the treatment of rheumatoid arthritis.负载铈锰氧化物纳米颗粒的微针用于靶向巨噬细胞治疗类风湿性关节炎。
J Nanobiotechnology. 2024 Mar 11;22(1):103. doi: 10.1186/s12951-024-02374-y.
4
Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis.肺结节病中肉芽肿性炎症的治疗
J Clin Med. 2024 Jan 27;13(3):738. doi: 10.3390/jcm13030738.
5
Dissolving microneedle patch-assisted transdermal delivery of methotrexate improve the therapeutic efficacy of rheumatoid arthritis. 微针贴片辅助透皮给药甲氨蝶呤改善类风湿关节炎的治疗效果。
Drug Deliv. 2023 Dec;30(1):121-132. doi: 10.1080/10717544.2022.2157518.
6
Association between Endodontic Infection, Its Treatment and Systemic Health: A Narrative Review.牙髓感染及其治疗与全身健康的关系：叙述性综述。
Medicina (Kaunas). 2022 Jul 14;58(7):931. doi: 10.3390/medicina58070931.
7
Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial.自体脂肪来源间充质干细胞治疗类风湿关节炎的安全性和有效性：一项 I/IIa 期、开放性、非随机、单臂试验。
Stem Cell Res Ther. 2022 Mar 3;13(1):88. doi: 10.1186/s13287-022-02763-w.
8
A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis Network Pharmacology and Molecular Docking.黄连解毒汤治疗类风湿关节炎潜在机制的初步探究：网络药理学与分子对接
Front Cell Dev Biol. 2022 Jan 19;9:740266. doi: 10.3389/fcell.2021.740266. eCollection 2021.
9
Network Pharmacology and Molecular Docking-Based Prediction of the Mechanism of Qianghuo Shengshi Decoction against Rheumatoid Arthritis.基于网络药理学和分子对接的羌活胜湿汤治疗类风湿关节炎作用机制预测。
Biomed Res Int. 2021 Sep 4;2021:6623912. doi: 10.1155/2021/6623912. eCollection 2021.
10
Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.类风湿关节炎患者一线生物治疗的决定因素：一项观察性研究的结果。
Medicine (Baltimore). 2021 May 14;100(19):e25943. doi: 10.1097/MD.0000000000025943.

本文引用的文献

1
Anaphylaxis: emergency management for health professionals.
Aust Prescr. 2018 Apr;41(2):54. doi: 10.18773/austprescr.2018.014. Epub 2018 Apr 3.
2
Rituximab in autoimmune diseases.利妥昔单抗在自身免疫性疾病中的应用
Aust Prescr. 2016 Aug;39(4):131-134. doi: 10.18773/austprescr.2016.053. Epub 2016 Aug 1.
3
Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.识别类风湿关节炎的 flares：OMERACT RA Flare 核心领域集的可靠性和构建验证。
RMD Open. 2016 May 26;2(1):e000225. doi: 10.1136/rmdopen-2015-000225. eCollection 2016.
4
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.甲氨蝶呤单药治疗以及甲氨蝶呤与传统和生物改善病情抗风湿药联合治疗类风湿关节炎：Cochrane系统评价缩编版及网状Meta分析
BMJ. 2016 Apr 21;353:i1777. doi: 10.1136/bmj.i1777.
5
Management of pregnancy in women with rheumatoid arthritis.类风湿关节炎女性的妊娠管理。
Med J Aust. 2016 Feb 1;204(2):62-3. doi: 10.5694/mja15.00365.
6
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2015 年美国风湿病学会类风湿关节炎治疗指南。
Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.
7
Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis.类风湿关节炎患者使用生物抗风湿疗法的感染风险。
Best Pract Res Clin Rheumatol. 2015 Apr;29(2):290-305. doi: 10.1016/j.berh.2015.05.009. Epub 2015 Jun 12.
8
Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.类风湿关节炎的疾病发作与关节损伤进展和残疾相关：BeSt研究的10年结果。
Arthritis Res Ther. 2015 Aug 31;17(1):232. doi: 10.1186/s13075-015-0730-2.
9
Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases.美国风湿病学会生殖健康峰会会议记录：自身免疫性和全身性炎症性疾病女性的生育、妊娠及哺乳管理
Arthritis Care Res (Hoboken). 2015 Mar;67(3):313-25. doi: 10.1002/acr.22516.
10
Methotrexate for treating rheumatoid arthritis.甲氨蝶呤用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD000957. doi: 10.1002/14651858.CD000957.pub2.